Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 5

1.

The role of alendronate in mitigating perimenopausal bone loss: a double-blind randomized controlled pilot study.

Mersereau JE, Khouri C, Jaffe RB.

Fertil Steril. 2010 Aug;94(3):1138-40. doi: 10.1016/j.fertnstert.2009.11.030. Epub 2010 Jan 8.

PMID:
20056199
2.

Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.

Iwamoto J, Takeda T, Sato Y.

Curr Med Res Opin. 2006 May;22(5):919-28. Review.

PMID:
16709313
3.

Ocular side effects of bisphosphonates: A case report and literature review.

McKague M, Jorgenson D, Buxton KA.

Can Fam Physician. 2010 Oct;56(10):1015-7. Review. No abstract available.

4.

[Influence on atherosclerosis of improvement of bone mineral density after medication for osteoporosis].

Yamada S, Inaba M, Nishizawa Y.

Nihon Rinsho. 2007 Nov 28;65 Suppl 9:348-51. Review. Japanese. No abstract available.

PMID:
18161129
5.

The impact of bone turnover and bone-active agents on bone quality: focus on the hip.

Dempster DW.

Osteoporos Int. 2002 May;13(5):349-52. Review. No abstract available.

PMID:
12086343

Supplemental Content

Support Center